Regentis Biomaterials Ltd. RGNT
1.98
(0.06)
(2.94%)
as of 25 Sep
- Market cap
- $15.8M
- P/E
- —
Follow RGNT
| Older periods | Dec '24 | Jun '25 | Dec '25 | Jun '26 | |
|---|---|---|---|---|---|
|
+1 more TTM period Free account |
— | — | — | 0.00% | |
| — | — | — | 0.00% | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
— | — | 0.00 | 0.00 | |
Free Cash Flow |
— | — | (3.58) | (5.20) | |
Capital Expenditures |
— | — | — | (0.03) | |
Piotroski F-Score |
— | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Cash ROIC |
0.00% | 0.00% | (26.85%) | (31.04%) | |
Accounts Payable Turnover |
— | — | — | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
— | — | 0.00 | 0.00 | |
Depreciation/Fixed assets |
— | — | — | 0.16 | |
Capex/Depreciation |
— | — | — | (6.60) | |
Operating CF per Share |
— | — | 0.00 | 0.00 | |
Capex per Share |
— | — | — | 0.00 | |
Capex to Sales |
— | — | — | 0.00 |
Columns are period end dates